Cannabis Science Inc (OTCMKTS:CBIS) is a penny play in the cannabis patch that we have covered a number of times in recent months. And our adventure with Cannabis Science stock is illustrative of a key concept with OTC stocks: If you dig too deep, you can miss the point. So, just look for the point.
In this case, we started off bearish on the name early last Fall, given the company’s long and checkered history of terrible shareholder dilution at every turn. However, by the late Fall, we got the point: they have something that can be sold to the public as “leadership in the medical marijuana game”, a narrative illustrated by their new relationship with the Dana Farber/Harvard Cancer Center (DF/HCC). For folks in the investment game who, after the November 8 voting, now need to show some kind of exposure to various elements of the cannabis revolution, that